Final announcement with agenda BBS Webinar: Statistical challenges in the clinical development of CAR T-cell therapies

Date: Monday, 22nd March 2021, 15:00-18:00 (CET)
Webinar: dial-in details will be communicated to registered participants

Please register until 18th March via the following form; after registration, in due time, participants will receive a calendar invite with the dial-in details.

The webinar is free of charge.


Link to recording

Roland MARION-GALLOIS, BMS, Switzerland Welcome and Introduction

Caroline ARBER BATH, CHUV, Switzerland Introduction to Cell Therapies: A Clinical Perspective

Elina ASIKANIUS, FIMEA, Finland Perspective from EMA

Zhenzhen XU, FDA, USA Perspective from FDA

Khadija RANTELL, MHRA, UK Phase 2 / Phase 3, Treatment effect or therapeutic strategy effect?

Alessandro PREVITALI, BMS, Switzerland Phase 2 / Phase 3, Estimands in the context of cell therapy development

Nigel YATEMAN, Novartis, Switzerland Challenges for new CAR-T therapies

Oriana CIANI, Università Bocconi, Italy Introduction on Post-Approval challenges, reimbursement and HTA assessments

Andrea SMITH, G-BA, Germany HTA-Perspective on the assessment of CAR-T-Cell Therapies

Marcelo PASQUINI and Zhenuan HU, CIBMTR, USA CAR-T cell therapy registries

Sorry, the comment form is closed at this time.